Actively Recruiting
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
Led by University of Pittsburgh · Updated on 2026-05-01
77
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
CONDITIONS
Official Title
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be 18 years of age or older
- Cytologically or histologically confirmed invasive breast cancer that is clinical stage I
- Tumor 2 cm or smaller on imaging
- Clinical node negative (cN0) and no distant metastasis (cM0)
- Tumor grade 2 or 3
- ECOG performance status of 0 to 2
- Estrogen receptor positive in 0% of cells (ER-negative)
- HER2-negative status (IHC 2+/FISH-negative or IHC 0 or 1+ with FISH-negative or untested)
- No prior chemotherapy for breast cancer
- Fit for chemotherapy and surgery
- Able to understand and willing to sign informed consent
- Willing to provide serial blood samples for the study
You will not qualify if you...
- History of other invasive cancers within the past 2 years
- Presence of synchronous, multifocal, or multicentric breast cancers
- Any medical or social condition that might prevent following the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UPMC Hillman Cancer
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
Research Team
K
Kelsey Mitch, BSN
CONTACT
L
Lucia M Borrasso, BSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here